S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA

S218: A PHASE I/II STUDY OF GOLIDOCITINIB, A SELECTIVE JAK1 INHIBITOR, IN REFRACTORY OR RELAPSED PERIPHERAL T CELL LYMPHOMA

Bibliographic Details
Main Authors:	W.-S. Kim, D.-H. Yoon, Y. Song, H. Yang, J. Cao, D. Ji, Y. Koh, H. Jing, H.-S. Eom, J.-Y. Kwak, W.-S. Lee, J.-S. Lee, H.-J. Shin, J. Jin, M. Wang, J. Li, X. Huang, X. Deng, Z. Yang, J. Zhu
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000843764.15785.8c

Similar Items

Pharmacokinetic characteristics of golidocitinib, a highly selective JAK1 inhibitor, in healthy adult participants
by: Kan Chen, et al.
Published: (2023-04-01)

Specific Mutation Predict Relapse/Refractory Diffuse Large B-Cell Lymphoma
by: Wang J, et al.
Published: (2024-09-01)

Gemcitabine, cisplatin, prednisone, and thalidomide for relapse and refractory peripheral T-cell lymphoma: a retrospective study from China
by: Liu X, et al.
Published: (2019-09-01)

S213: EFFICACY AND SAFETY OF HUMANIZED VERSUS MURINIZED CD19 AND CD22 CAR-T CELL COCKTAIL THERAPY FOR REFRACTORY/RELAPSED B-CELL LYMPHOMA
by: L. Huang, et al.
Published: (2022-06-01)

S215: GEMSTONE-201: PRE-PLANNED PRIMARY ANALYSIS OF A MULTICENTER, SINGLE-ARM, PHASE 2 STUDY OF SUGEMALIMAB IN PATIENTS WITH RELAPSED OR REFRACTORY EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA (R/R ENKTL)
by: H. Huang, et al.
Published: (2022-06-01)

A new isomeric state in 218Pa
by: M.M. Zhang, et al.
Published: (2020-01-01)

P1096: TREATMENT PATTERNS AND OUTCOMES IN RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA
by: A. Bock, et al.
Published: (2022-06-01)

Nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma: modest activity and cases of hyperprogression
by: Hyo Jin Kim, et al.
Published: (2022-06-01)

P1119: THE ORAL PI3KΔ INHIBITOR LINPERLISIB FOR THE TREATMENT OF RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: A SINGLE-ARM MULTICENTER PHASE 2 CLINICAL TRIAL
by: T. wang, et al.
Published: (2022-06-01)

Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results
by: Shinya Rai, et al.
Published: (2022-10-01)

P1111: COMPARATIVE EFFICACY AND SAFETY OF TISAGENLECLEUCEL AND AXICABTAGENE CILOLEUCEL IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA
by: M. Dickinson, et al.
Published: (2022-06-01)

P378: THE PROGNOSIS FACTORS OF CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY B-ALL
by: Y. Wang, et al.
Published: (2022-06-01)

P1218: FIRST-IN-HUMAN STUDY OF CD19/BCMA DUAL-TARGETING FAST CAR-T GC012F FOR PATIENTS WITH RELAPSED/REFRACTORY B-CELL NON-HODGKIN’S LYMPHOMA
by: X. Chen, et al.
Published: (2022-06-01)

P684: PHASE 1 STUDY OF LP-108, A SELECTIVE BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
by: W. Xu, et al.
Published: (2022-06-01)

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma
by: Eric Van Den Neste, et al.
Published: (2018-05-01)

NANATINOSTAT WITH OR WITHOUT VALGANCICLOVIR IN PATIENTS WITH RELAPSED/REFRACTORY EBV-POSITIVE PERIPHERAL T-CELL LYMPHOMA (NAVAL-1 STAGE 1)
by: M Lacerda, et al.
Published: (2024-10-01)

P977: BISPECIFIC CS1-BCMA CAR-T CELLS ARE CLINICALLY ACTIVE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA
by: C. Li, et al.
Published: (2022-06-01)

Safety and Efficacy of Pralatrexate in the Management of Relapsed or Refractory Peripheral T-cell Lymphoma
by: Annabelle L. Rodd, et al.
Published: (2012-01-01)

PB2064: RELAPSED/REFRACTORY HODGKIN LYMPHOMA PATIENTS TREATED WITH RADIOTHERAPY
by: F. Kallel, et al.
Published: (2022-06-01)

Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
by: A Boland, et al.
Published: (2009-09-01)

PB2144: PEARL: A STUDY TO ASSESS THE EFFICACY AND SAFETY OF PENPULIMAB PLUS LENALIDOMIDE, RITUXIMAB, GEMCITABINE AND OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA
by: X. Wei, et al.
Published: (2022-06-01)

P1200: RELAPSE AND OCCURRENCE OF SECOND PRIMARY MALIGNANCIES IN PATIENTS WITH DIFFUSE LARGE B CELL LYMPHOMA IN RITUXIMAB ERA, A NATIONWIDE OBSERVATIONAL STUDY
by: H. J. Lee, et al.
Published: (2022-06-01)

Relapsed/Refractory Hodgkin Lymphoma
by: Semira Sheikh, et al.
Published: (2018-06-01)

P1124: MOSUNETUZUMAB RETREATMENT IS EFFECTIVE AND WELL-TOLERATED IN PATIENTS WITH RELAPSED OR REFRACTORY B-CELL NON-HODGKIN LYMPHOMA
by: C. Y. Cheah, et al.
Published: (2022-06-01)

Long-term efficacy and safety of tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: final analysis of phase IIb results
by: Shinya Rai, et al.
Published: (2024-06-01)

Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study
by: Ma X, et al.
Published: (2020-01-01)

The Efficacy and Safety of Apatinib in Refractory/Relapse Advanced Pediatric Solid Tumor: A Retrospective Study
by: Sun F, et al.
Published: (2020-07-01)

P1240: ANTI-PD-1-ANTIBODY (TISLELIZUMAB) COMBINED WITH DEACETYLASE INHIBITOR (CHIDAMIDE), LENALIDOMIDE AND ETOPOSIDE FOR THE TREATMENT OF REFRACTORY/RELAPSED EXTRANODAL NATURAL KILLER/T CELL LYMPHOMA, NASAL
by: L. Zhang, et al.
Published: (2022-06-01)

Pilot trial of ibrutinib in patients with relapsed or refractory T-cell lymphoma
by: Anita Kumar, et al.
Published: (2018-04-01)

The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
by: Tingxun Lu, et al.
Published: (2023-08-01)

Economic Evaluation of Adding Daratumumab to Carfilzomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma
by: Yi L, et al.
Published: (2024-11-01)

S207: EFFICACY AND SAFETY OF A THIRD GENERATION CD20 CART (MB-106) FOR TREATMENT OF RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL)
by: M. Shadman, et al.
Published: (2022-06-01)

Concurrent use of rabacfosadine and L‐asparaginase for relapsed or refractory multicentric lymphoma in dogs
by: Jacob R. Cawley, et al.
Published: (2020-03-01)

Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma
by: Esther Wei Yin Chang, et al.
Published: (2024-06-01)

TREATMENT OF RELAPSE AND REFRACTORY HODGKIN LYMPHOMA
by: E. A. Baryakh
Published: (2017-06-01)

P591: PRELIMINARY RESULTS OF A PHASE I STUDY OF CLIFUTINIB, A HIGHLY SELECTIVE, POTENT ORAL FLT-3 INHIBITOR, IN PATINETS WITH FLT3-MUTATED RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA
by: W. Yu, et al.
Published: (2022-06-01)

The LINC01176-miR-218-5p-IL-36G Network is Responsible for the Pathogenesis of Psoriasis by Promoting Inflammation
by: Zhao Z, et al.
Published: (2024-01-01)

Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China
by: Yuankai Shi, et al.
Published: (2017-03-01)

S264: PRELIMINARY ANALYSES OF A NON-GENE-EDITING ALLOGENTIC CAR-T IN CD19+ RELAPSED OR REFRACTORY NON-HODGIN’S LYMPHOMA
by: X. Wang, et al.
Published: (2022-06-01)

P1239: TISLELIZUMAB, A PD-1 INHIBITOR FOR RELAPSED/REFRACTORY MATURE T- AND NK-CELL NEOPLASMS: RESULTS FROM A PHASE 2 STUDY
by: E. Bachy, et al.
Published: (2022-06-01)